Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kB.
Background
Endothelial MAdCAM-1 (mucosal addressin cell adhesion molecule-1) expression is associated with the oxidant-dependent induction and progress of inflammatory bowel disease (IBD). Melatonin, a relatively safe, potent antioxidant, has shown efficacy in several chronic injury models may limit MAdCAM-1 expression and therefore have a therapeutic use in IBD.
Methods
We examined how different doses of melatonin reduced endothelial MAdCAM-1 induced by TNF-a in an in vitro model of lymphatic endothelium. Endothelial monolayers were pretreated with melatonin prior to, and during an exposure, to TNF-a (1 ng/ml, 24 h), and MAdCAM-1 expression measured by immunoblotting.
Results
MAdCAM-1 was induced by TNF-a. Melatonin at concentrations over 100 μm (10-4 M) significantly attenuated MAdCAM-1 expression and was maximal at 1 mM.
Conclusions
Our data indicate that melatonin may exert therapeutic activity in IBD through its ability to inhibit NF-kB dependent induction of MAdCAM-1.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| bureauCode |
[
"009:25"
]
|
| contactPoint |
{
"fn": "NIH",
"@type": "vcard:Contact",
"hasEmail": "mailto:info@nih.gov"
}
|
| description | Background Endothelial MAdCAM-1 (mucosal addressin cell adhesion molecule-1) expression is associated with the oxidant-dependent induction and progress of inflammatory bowel disease (IBD). Melatonin, a relatively safe, potent antioxidant, has shown efficacy in several chronic injury models may limit MAdCAM-1 expression and therefore have a therapeutic use in IBD. Methods We examined how different doses of melatonin reduced endothelial MAdCAM-1 induced by TNF-a in an in vitro model of lymphatic endothelium. Endothelial monolayers were pretreated with melatonin prior to, and during an exposure, to TNF-a (1 ng/ml, 24 h), and MAdCAM-1 expression measured by immunoblotting. Results MAdCAM-1 was induced by TNF-a. Melatonin at concentrations over 100 μm (10-4 M) significantly attenuated MAdCAM-1 expression and was maximal at 1 mM. Conclusions Our data indicate that melatonin may exert therapeutic activity in IBD through its ability to inhibit NF-kB dependent induction of MAdCAM-1. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Official Government Data Source",
"mediaType": "text/html",
"description": "Visit the original government dataset for complete information, documentation, and data access.",
"downloadURL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC111062/"
}
]
|
| identifier | https://healthdata.gov/api/views/8h8t-4czt |
| issued | 2025-07-14 |
| keyword |
[
"inflammatory-bowel-disease",
"madcam-1-expression",
"melatonin-treatment",
"nih",
"tnf-alpha"
]
|
| landingPage | https://healthdata.gov/d/8h8t-4czt |
| modified | 2025-09-06 |
| programCode |
[
"009:033"
]
|
| publisher |
{
"name": "National Institutes of Health",
"@type": "org:Organization"
}
|
| theme |
[
"NIH"
]
|
| title | Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kB. |
